{
  "docId": "019de074-48ca-708b-9817-9b094467f30f",
  "docSlug": "b3581031b12373a5077a05b88a8907f5",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 45,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The slide uses a navigation bar at the top to indicate the current section (BioPharmaceuticals).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-48ca-708b-9817-9b094467f30f/22",
  "deckHref": "/decks/019de074-48ca-708b-9817-9b094467f30f",
  "deckJsonHref": "/decks/019de074-48ca-708b-9817-9b094467f30f.json",
  "deckAnchorHref": "/decks/019de074-48ca-708b-9817-9b094467f30f#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.68,
        "y": 0.345
      },
      "kind": "chart",
      "text": "V&I Revenue Breakdown",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49c99a00-a382-4040-8ccb-e7ebb1d7a5c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.04,
        "y": 0.345
      },
      "kind": "chart",
      "text": "CVRM Revenue Breakdown",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b2bd1a6-4716-4381-b4d0-1d135cc263e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.36,
        "y": 0.345
      },
      "kind": "chart",
      "text": "R&I Revenue Breakdown",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfabd717-95ff-488b-9ee4-434f2f2a9022",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "Growth rates for BioPharmaceuticals and CVRM are pro forma. CER = constant exchange rates; R&I = Respiratory & Immunology; CVRM = Cardiovascular, Renal & Metabolism; V&I = Vaccine & Immune Therapies; SGLT2i = sodium glucose co-transporter-2 inhibitor; IL-5 = interleukin-5. EUA = Emergency Use Authorisation. Collaboration partners: Amgen (Tezspire), Sanofi (Beyfortus).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "154c0900-b182-4cb1-a16a-3c77bbe91f8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.37,
        "y": 0.715
      },
      "kind": "list",
      "text": "Fasenra +15% to $1.4bn, leading IL-5 biologic; Tezspire +57% sequential growth in Q4; Saphnelo +43% sequential growth in Q4",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12d763ea-06a9-401b-925f-8429f6b38674",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.28,
        "x": 0.05,
        "y": 0.715
      },
      "kind": "list",
      "text": "Farxiga +56% to $4.4bn, SGLT2i global leader",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28792087-cf29-4dd6-abda-dea349a1827a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.69,
        "y": 0.715
      },
      "kind": "list",
      "text": "Evusheld Q4 $734m; Vaxzevria Q4 $95m, decline reflects decreased demand",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "728f9d38-2ebd-491b-9573-0809161224fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Total Revenue $20bn, +11% at CER, driven by Farxiga strength and R&I launches",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31a3a5ff-68b6-49b7-b891-1ab2a462961d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "BioPharmaceuticals: FY 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a29e99de-63d4-47d7-9cc3-0e93e2092d9f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}